Invivyd Q4 revenue up 25% YoY to $17.2mln, cash at $226.7mln.

• Invivyd Q4 2025 PEMGARDA net revenue: $17.2 million, 25% YoY growth • 2025 year-end cash: $226.7 million • Declaring Phase 3 trial for COVID vaccine alternative VYD2311 initiated • Fast Track designation granted for VYD2311 • Declaring trial on track with full enrollment achieved • VYD2311 safety data review completed, IDMC recommends trial continuation

Invivyd, Inc. (Nasdaq: IVVD) reported preliminary fourth-quarter 2025 net product revenue of $17.2 million for PEMGARDA® (pemivibart), reflecting 25% year-over-year growth and 31% quarter-over-quarter growth. The company also disclosed year-end 2025 cash and cash equivalents of $226.7 million, following over $200 million in capital raises during the second half of 2025.

The company initiated its Phase 3 DECLARATION trial for VYD2311, a monoclonal antibody candidate designed as a vaccine-alternative for COVID-19 prevention. The trial, which has achieved full enrollment of 1,770 participants, received Fast Track designation from the FDA in December 2025. An Independent Data Monitoring Committee (IDMC) reviewed unblinded safety data and recommended trial continuation, including enrollment of pregnant and breastfeeding women.

VYD2311's development remains a strategic focus, with top-line data anticipated mid-2026. The molecule leverages Invivyd's proprietary technology platform and builds on the safety profile of its prior monoclonal antibody, PEMGARDA. The company also highlighted progress in pipeline expansion, including preclinical efforts for RSV and measles candidates.

Financially, Invivyd attributed PEMGARDA's revenue growth to commercial execution and demand for monoclonal antibody prophylaxis amid evolving vaccination trends. Management emphasized the balance sheet's strength in supporting ongoing trials and potential commercialization of VYD2311, should regulatory approval be secured.

The company is scheduled to host a conference call on March 5, 2026 to discuss full-year results and business updates.